Conference Coverage
ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
241-255 of 521
Recognizing and Addressing Medical Gaslighting in Healthcare
NeuroFrontiersRecognizing and Addressing Medical Gaslighting in Healthcare
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC Action CenterPromising results for APOC3 ASO in familial chylomicronemia syndrome
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC Action CenterIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Self-assessment on statin eligibility without prescription using a web app
ACC Action CenterSelf-assessment on statin eligibility without prescription using a web app
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
ACC Action CenterMore than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Stopping aspirin after 1 month DAPT in ACS patients after stenting
ACC Action CenterStopping aspirin after 1 month DAPT in ACS patients after stenting
- advertisement
Head-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
ACC Action CenterHead-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
ACC Action CenterAPOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC Action CenterNo improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC Action CenterEarly aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
ACC Action CenterNo effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Children Achieve Year-Long HIV Remission After Treatment Pause
Clinician's RoundtableChildren Achieve Year-Long HIV Remission After Treatment Pause
- advertisement
Assessing Interest in Oral vs. LAI ART Among Women with HIV
Clinician's RoundtableAssessing Interest in Oral vs. LAI ART Among Women with HIV
A Potential Treatment for Parkinson's Disease Showing Safety and Tolerability
NeuroFrontiersA Potential Treatment for Parkinson's Disease Showing Safety and Tolerability
Research Identifies a Potential Link Between Sleep Apnea and Memory Loss
NeuroFrontiersResearch Identifies a Potential Link Between Sleep Apnea and Memory Loss
